Skip to main content
main-content

The independent medical news service

Prostate cancer

13-08-2019 | Oncology | Highlight | Article

Meta-analysis supports MRI plus targeted biopsy for prostate cancer diagnosis

Prebiopsy multiparametric magnetic resonance imaging plus targeted biopsy is associated with increased detection of clinically significant prostate cancer versus ultrasonography-guided systematic biopsy alone, study data show.

09-08-2019 | Prostate cancer | News | Article

‘Superior’ detection of biochemical recurrence with PSMA PET–CT

68Ga-prostate-specific membrane antigen-11 should be the “tracer of choice” for PET–CT to detect the postoperative biochemical recurrence of prostate cancer, say researchers who conducted a comparative imaging trial.

05-08-2019 | Oncology | News | Article

HIV infection associated with worse prostate cancer outcomes

Older individuals with HIV and prostate cancer have worse outcomes than corresponding cancer patients without HIV, according to a large database study from the USA.

02-08-2019 | Oncology | News | Article

Darolutamide added to armamentarium for nonmetastatic CRPC

Read more about this US FDA approval here

30-07-2019 | Oncology | Main feed | News

Decision aids unlikely to influence men considering prostate cancer screening

Current decision aids probably have no influence on whether physicians and patients discuss prostate cancer screening or decide to undergo screening, according to a systematic review and meta-analysis.

17-07-2019 | Oncology | News | Article

ADT use associated with Alzheimer’s disease, dementia

Older prostate cancer patients who use androgen deprivation therapy may be at increased risk for developing Alzheimer’s disease or dementia, findings indicate.

11-07-2019 | Oncology | News | Article

Conservative management increasing in younger prostate cancer patients

Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.

10-07-2019 | Oncology | News | Article

Glucocorticoid regimens explored in mCRPC

Combining abiraterone acetate with a relatively high dose of prednisone or dexamethasone may reduce mineralocorticoid excess toxic effects, but can result in increased metabolic toxicity, study data show.

04-07-2019 | Oncology | News | Article

EBRT has smallest impact on sexual function after prostate cancer diagnosis

Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.

21-06-2019 | Oncology | News | Article

Race-based difference in survival with sipuleucel-T therapy confirmed

Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.

14-06-2019 | Oncology | News | Article

ENZAMET supports enzalutamide use in men with metastatic CSPC

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

04-06-2019 | Oncology | News | Article

Metformin addition ruled out for nondiabetic men with metastatic CRPC

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

03-06-2019 | Oncology | News | Article

Olaparib response may depend on DDR mutation type in mCRPC

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

02-06-2019 | Oncology | News | Article

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

01-06-2019 | Oncology | News | Article

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

28-05-2019 | Oncology | News | Article

Socioeconomic factors major players in prostate cancer racial disparity

Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.

20-05-2019 | Oncology | News | Article

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

09-05-2019 | Oncology | News | Article

5α-reductase inhibitors linked to elevated prostate cancer death rates

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

03-05-2019 | Oncology | News | Article

Biosimilar pegfilgrastim receives EMA go-ahead, generic cabazitaxel does not

Read more on these announcements here

02-05-2019 | Prostate cancer | News | Article

Single HDR brachytherapy treatment effective for low-risk prostate cancer

A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.

Image Credits